{"transactions":[{"id":4638284,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":21552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638283,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":41552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638282,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":61552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638281,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":110.51,"value":22102.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638280,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":11900,"price":109.995,"value":1308940.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767980,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638279,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":3090,"price":108.908,"value":336525.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":779880,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638278,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"sale","planned":true,"acquired":false,"shares":4810,"price":108.179,"value":520340.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":782970,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638277,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-08","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638276,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":200,"price":113.693,"value":22738.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638275,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":900,"price":112.78,"value":101502.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767980,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638274,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":10300,"price":111.839,"value":1151941.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":768880,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638273,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":8600,"price":111.031,"value":954866.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":779180,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638272,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-07","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638271,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":1780,"price":110.812,"value":197245.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638270,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":9920,"price":109.891,"value":1090118.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":769560,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638269,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":109.334,"value":656004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":779480,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638268,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":107.902,"value":248174.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":785480,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638267,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-10-08T23:56:19.000Z","date":"2026-10-06","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000140","document":"wk-form4_1791503775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000140/wk-form4_1791503775.xml","form_type":"4"}},{"id":4638265,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-08T23:55:35.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":3796,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents annual restricted stock unit (\"RSU\") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders."},{"field":"shares","element":"transactionShares","label":"F2","text":"This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4/A amends the Form 4 filed on May 7, 2026 solely to correct the number of RSUs acquired and the amount of securities beneficially owned following the reported transaction. The original filing reported 6,796 RSUs acquired. The correct number of RSUs acquired was 3,796. As a result, the amount of securities beneficially owned following the transaction has been revised accordingly."}],"balance_after":42294,"source":{"system":"sec-edgar","filing":"0001159036-26-000139","document":"wk-form4a_1791503732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662521/000115903626000139/wk-form4a_1791503732.xml","form_type":"4/A","original_submission_date":"2026-05-07"}},{"id":4634003,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-10-03T00:43:41.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1775,"derivative":{"exercise_price":106.94,"expiration_date":"2036-10-01","underlying":"Common Stock","underlying_shares":1775},"source":{"system":"sec-edgar","filing":"0001159036-26-000136","document":"wk-form4_1790973818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000136/wk-form4_1790973818.xml","form_type":"4"}},{"id":4634002,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":30154,"kind":"person","name":"Daly James M","position":1,"cik":"0001560782","reported_name":"Daly James M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-10-03T00:43:41.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the\ndate of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1169,"source":{"system":"sec-edgar","filing":"0001159036-26-000136","document":"wk-form4_1790973818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000136/wk-form4_1790973818.xml","form_type":"4"}},{"id":4634009,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":110.04,"value":11004.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."}],"balance_after":53609,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4634008,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":109.569,"value":120525.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":53709,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4634007,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3300,"price":108.454,"value":357898.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":54809,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4634006,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-03T00:38:18.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":730,"price":107.168,"value":78232.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58109,"source":{"system":"sec-edgar","filing":"0001159036-26-000133","document":"wk-form4_1790973495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000133/wk-form4_1790973495.xml","form_type":"4"}},{"id":4621732,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":108.991,"value":435964.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":58839,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4621731,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":8896,"price":108.04,"value":961123.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":62839,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4621730,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":106.828,"value":320484.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":71735,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4621729,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":36354,"kind":"person","name":"Posard Matthew L.","position":1,"cik":"0001543792","reported_name":"Posard Matthew L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T21:19:45.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":3100,"price":106.132,"value":329009.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":74735,"source":{"system":"sec-edgar","filing":"0001159036-26-000123","document":"wk-form4_1789679983.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1543792/000115903626000123/wk-form4_1789679983.xml","form_type":"4"}},{"id":4616544,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of\ngrant was February 14, 2018."}],"balance_after":81552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616543,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of\ngrant was February 14, 2018."}],"balance_after":101552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616542,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of\ngrant was February 14, 2018."}],"balance_after":121552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616541,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":4508,"price":107.548,"value":484826.384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.400 to $107.960. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616540,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":15492,"price":107.154,"value":1660029.768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.400 to $107.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":772288,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616539,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616538,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":5412,"price":107.581,"value":582228.372,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.360 to $107.820 The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616537,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":14588,"price":107.012,"value":1561091.056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.360 to $107.350 The Reporting Person has provided to the issuer, and will provide to any\nsecurity holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range"}],"balance_after":773192,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616536,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616535,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":100,"price":108.67,"value":10867.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616534,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":6596,"price":107.821,"value":711187.316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.640 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767880,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616533,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":13304,"price":107.222,"value":1426481.488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.640 to $107.632. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":774476,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":4616532,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-09-12T00:35:17.000Z","date":"2026-09-09","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The\nsales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000119","document":"wk-form4_1789173314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528185/000115903626000119/wk-form4_1789173314.xml","form_type":"4"}},{"id":904,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-09-02T20:59:28.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":1778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1778,"derivative":{"exercise_price":107.72,"expiration_date":"2036-09-01","underlying":"Common Stock","underlying_shares":1778},"source":{"system":"sec-edgar","filing":"0001159036-26-000117","document":"wk-form4_1788382766.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000115903626000117/wk-form4_1788382766.xml","form_type":"4"}},{"id":903,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":794,"kind":"person","name":"Appelhans Dannielle","position":1,"cik":"0001874962","reported_name":"Appelhans Dannielle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-02T20:59:28.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":1161,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the\ndate of the Issuer's 2027 annual meeting of stockholders."}],"balance_after":1161,"source":{"system":"sec-edgar","filing":"0001159036-26-000117","document":"wk-form4_1788382766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1874962/000115903626000117/wk-form4_1788382766.xml","form_type":"4"}},{"id":681850,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":141552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681849,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":161552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681848,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant\nwas February 14, 2018."}],"balance_after":181552,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681847,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":107.765,"value":344848.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.69 to $107.900 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681846,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":9600,"price":107.224,"value":1029350.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.69 to $107.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":770980,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681845,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":7200,"price":106.358,"value":765777.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.69 to $106.680 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":780580,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681844,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-19","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681843,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":9400,"price":104.874,"value":985815.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $104.585 to $105.080 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681842,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":4897,"price":104.11,"value":509826.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.570 to $104.550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":777180,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681841,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":5703,"price":103.083,"value":587882.349,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.550 to $103.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":782077,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681840,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681839,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":103.482,"value":776115.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $103.160 to $104.010. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681838,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":102.553,"value":922977.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $102.140 to $103.050. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":775280,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681837,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":101.766,"value":213708.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $101.140 to $102.120. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":784280,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681836,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":500,"price":100.457,"value":50228.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $99.980 to $100.780. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786380,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681835,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":900,"price":98.958,"value":89062.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $98.580 to $99.210. The Reporting Person has provided to the issuer, and will provide to any security\nholder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786880,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":681834,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-08-20T00:01:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":18.41,"value":368200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales\nof common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000108","document":"wk-form4_1787184072.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000108/wk-form4_1787184072.xml","form_type":"4"}},{"id":691048,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T21:43:57.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":1626,"price":102.8,"value":167152.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":40418,"source":{"system":"sec-edgar","filing":"0001662521-26-000002","document":"wk-form4_1786484634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000166252126000002/wk-form4_1786484634.xml","form_type":"4"}},{"id":712025,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":1923,"price":12.07,"value":23210.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":0,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":1923},"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":712024,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":1035,"price":80.187,"value":82993.545,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $79.710 to $80.490. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":712023,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":888,"price":79.276,"value":70397.088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.710 to $79.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":768815,"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":712022,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-07-09T21:19:34.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":1923,"price":12.07,"value":23210.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":769703,"source":{"system":"sec-edgar","filing":"0001159036-26-000100","document":"wk-form4_1783631972.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000100/wk-form4_1783631972.xml","form_type":"4"}},{"id":718813,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33113,"kind":"person","name":"RAMSAY DAVID A","position":1,"cik":"0001283292","reported_name":"RAMSAY DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, PRESIDENT, DRUG DELIVERY"}}],"security":"Option to Purchase Common Stock","published_at":"2026-07-02T20:45:54.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":39823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":39823,"derivative":{"exercise_price":77.01,"exercise_date":"2027-07-01","expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":39823},"source":{"system":"sec-edgar","filing":"0001159036-26-000096","document":"wk-form4_1783025152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000096/wk-form4_1783025152.xml","form_type":"4"}},{"id":718812,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33113,"kind":"person","name":"RAMSAY DAVID A","position":1,"cik":"0001283292","reported_name":"RAMSAY DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, PRESIDENT, DRUG DELIVERY"}}],"security":"Restricted Stock Units","published_at":"2026-07-02T20:45:54.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":16232,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":16232,"derivative":{"exercise_price":0,"exercise_date":"2027-07-01","underlying":"Common Stock","underlying_shares":16232},"source":{"system":"sec-edgar","filing":"0001159036-26-000096","document":"wk-form4_1783025152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000096/wk-form4_1783025152.xml","form_type":"4"}},{"id":718811,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33113,"kind":"person","name":"RAMSAY DAVID A","position":1,"cik":"0001283292","reported_name":"RAMSAY DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, PRESIDENT, DRUG DELIVERY"}}],"security":"Restricted Stock Units","published_at":"2026-07-02T20:45:54.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.  The shares received upon vesting remain subject to a one-year holding period from the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.  The shares received upon vesting remain subject to a one-year holding period from the vesting date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000096","document":"wk-form4_1783025152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000096/wk-form4_1783025152.xml","form_type":"4"}},{"id":718810,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33113,"kind":"person","name":"RAMSAY DAVID A","position":1,"cik":"0001283292","reported_name":"RAMSAY DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, PRESIDENT, DRUG DELIVERY"}}],"security":"Common Stock","published_at":"2026-07-02T20:45:54.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":5408,"price":78.27,"value":423284.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":4592,"source":{"system":"sec-edgar","filing":"0001159036-26-000096","document":"wk-form4_1783025152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000096/wk-form4_1783025152.xml","form_type":"4"}},{"id":718809,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33113,"kind":"person","name":"RAMSAY DAVID A","position":1,"cik":"0001283292","reported_name":"RAMSAY DAVID A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, PRESIDENT, DRUG DELIVERY"}}],"security":"Common Stock","published_at":"2026-07-02T20:45:54.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001159036-26-000096","document":"wk-form4_1783025152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000096/wk-form4_1783025152.xml","form_type":"4"}},{"id":718808,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33112,"kind":"person","name":"Snellgrove Darren","position":1,"cik":"0002137401","reported_name":"Snellgrove Darren","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2026-07-02T20:44:01.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":127432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":127432,"derivative":{"exercise_price":77.01,"exercise_date":"2027-07-01","expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":127432},"source":{"system":"sec-edgar","filing":"0001159036-26-000095","document":"wk-form4_1783025038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000095/wk-form4_1783025038.xml","form_type":"4"}},{"id":718807,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":33112,"kind":"person","name":"Snellgrove Darren","position":1,"cik":"0002137401","reported_name":"Snellgrove Darren","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-02T20:44:01.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":41554,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This award vests one-third on the first anniversary of the grant date and then one-third on each anniversary date thereafter."}],"balance_after":41554,"derivative":{"exercise_price":0,"exercise_date":"2027-07-01","underlying":"Common Stock","underlying_shares":41554},"source":{"system":"sec-edgar","filing":"0001159036-26-000095","document":"wk-form4_1783025038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000095/wk-form4_1783025038.xml","form_type":"4"}},{"id":718806,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:42:08.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":625,"price":77.209,"value":48255.625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.950 to $77.710. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42044,"source":{"system":"sec-edgar","filing":"0001159036-26-000094","document":"wk-form4_1783024925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000094/wk-form4_1783024925.xml","form_type":"4"}},{"id":718805,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:42:08.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":76.395,"value":76395.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.930 to $76.850. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":42669,"source":{"system":"sec-edgar","filing":"0001159036-26-000094","document":"wk-form4_1783024925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000094/wk-form4_1783024925.xml","form_type":"4"}},{"id":723031,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":34532,"kind":"person","name":"Krishnan Mahesh","position":1,"cik":"0001866746","reported_name":"Krishnan Mahesh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-30T21:25:10.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":7304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to Reporting Person of options exercisable as of April 25, 2025."}],"balance_after":1500,"derivative":{"exercise_price":38.46,"expiration_date":"2034-04-25","underlying":"Common Stock","underlying_shares":7304},"source":{"system":"sec-edgar","filing":"0001159036-26-000082","document":"wk-form4_1782854707.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000082/wk-form4_1782854707.xml","form_type":"4"}},{"id":723030,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":34532,"kind":"person","name":"Krishnan Mahesh","position":1,"cik":"0001866746","reported_name":"Krishnan Mahesh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:25:10.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7304,"price":75,"value":547800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1."}],"balance_after":14462,"source":{"system":"sec-edgar","filing":"0001159036-26-000082","document":"wk-form4_1782854707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000082/wk-form4_1782854707.xml","form_type":"4"}},{"id":723029,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":34532,"kind":"person","name":"Krishnan Mahesh","position":1,"cik":"0001866746","reported_name":"Krishnan Mahesh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:25:10.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":7304,"price":38.46,"value":280911.84,"ownership":{"direct":true},"balance_after":21766,"source":{"system":"sec-edgar","filing":"0001159036-26-000082","document":"wk-form4_1782854707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000082/wk-form4_1782854707.xml","form_type":"4"}},{"id":738199,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2026-06-15T20:09:46.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":false,"shares":5034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":10068,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5034},"source":{"system":"sec-edgar","filing":"0001159036-26-000077","document":"wk-form4_1781554184.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000077/wk-form4_1781554184.xml","form_type":"4"}},{"id":738198,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-15T20:09:46.000Z","date":"2026-06-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":2715,"price":69.5,"value":188692.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":49929,"source":{"system":"sec-edgar","filing":"0001159036-26-000077","document":"wk-form4_1781554184.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000077/wk-form4_1781554184.xml","form_type":"4"}},{"id":738197,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":38287,"kind":"person","name":"Snyder Mark Howard","position":1,"cik":"0001902866","reported_name":"Snyder Mark Howard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF LEGAL OFFICER"}}],"security":"Common Stock","published_at":"2026-06-15T20:09:46.000Z","date":"2026-06-12","kind":"exercise","planned":false,"acquired":true,"shares":5034,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52644,"source":{"system":"sec-edgar","filing":"0001159036-26-000077","document":"wk-form4_1781554184.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000077/wk-form4_1781554184.xml","form_type":"4"}},{"id":752489,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":1923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752488,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":11923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752487,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":31923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752486,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":6100,"price":69.692,"value":425121.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752485,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":68.736,"value":137472.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":773880,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752484,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":67.675,"value":101512.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":775880,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752483,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":400,"price":66.368,"value":26547.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":777380,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752482,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":777780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752481,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":3400,"price":66.745,"value":226933.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752480,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":16600,"price":66.314,"value":1100812.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":771180,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752479,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-02","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752478,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":5401,"price":68.346,"value":369136.746,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":767780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752477,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":12989,"price":67.41,"value":875588.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":773181,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752476,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1610,"price":66.388,"value":106884.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":786170,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":752475,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-06-04T00:06:58.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027."}],"balance_after":787780,"source":{"system":"sec-edgar","filing":"0001159036-26-000074","document":"wk-form4_1780531615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000074/wk-form4_1780531615.xml","form_type":"4"}},{"id":755419,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":24717,"kind":"person","name":"Connaughton Bernadette","position":1,"cik":"0001662521","reported_name":"Connaughton Bernadette","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T21:20:34.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":1625,"price":66.21,"value":107591.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1."}],"balance_after":43669,"source":{"system":"sec-edgar","filing":"0001159036-26-000072","document":"wk-form4_1780435230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000072/wk-form4_1780435230.xml","form_type":"4"}},{"id":781214,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":51923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781213,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":61923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}},{"id":781212,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":21780,"kind":"person","name":"Torley Helen","position":1,"cik":"0001528185","reported_name":"Torley Helen","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Option to Purchase Common Stock","published_at":"2026-05-13T21:50:19.000Z","date":"2026-05-11","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":12.07,"value":241400.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017."}],"balance_after":81923,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001159036-26-000070","document":"wk-form4_1778709013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000070/wk-form4_1778709013.xml","form_type":"4"}}],"next_cursor":"2026-05-13T21:50:19.000000Z,781212"}